Benzinga | Dec 10, 2021 06:51AM EST

Oppenheimer Upgrades Aurinia Pharmaceuticals to Outperform, Lowers Price Target to $31

Oppenheimer analyst Justin Kim upgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Perform to Outperform and lowers the price target from $33 to $31.